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Cellular therapy is reaching a pinnacle with an understanding of the potential of human mesenchymal stem cells (hMSCs) to
regenerate damaged tissue in the body. The limited numbers of these hMSCs in currently identiﬁed sources, like bone marrow,
adipose tissue, and so forth, bring forth the need for their in vitro culture/expansion. However, the extensive usage of supplements
containing xenogeneic components in the expansion-media might pose a risk to the post-transplantation safety of patients.
This warrants the necessity to identify and develop chemically deﬁned or “humanized” supplements which would make in vitro
cultured/processed cells relatively safer for transplantation in regenerative medicine. In this paper, we outline the various caveats
associated with conventionally used supplements of xenogenic origin and also portray the possible alternatives/additives which
could one day herald the dawn of a new era in the translation of in vitro cultured cells to therapeutic interventions.
1.Introduction
Human mesenchymal stem cells (hMSCs) are undoubtedly
one of the most promising types of adult stem cells (ASCs)
forcell-basedtherapiescurrentlybeingtestedinclinicaltrials
for a wide range of ailments (e.g., brain and spinal cord
injury, cardiovascular disease and myocardial infarction
(MI), type I diabetes, multiple sclerosis, Crohn’s disease,
cartilage and bone injury, and graft-versus-host disease
(GVHD) during bone marrow transplantation) [1]. The
general practice includes isolation of hMSCs from various
sources like bone marrow, adipose tissue, skeletal muscle,
umbilical cord blood, umbilical cord matrix, peripheral
blood, dental pulp, and amniotic ﬂuid and its expansion
under in vitro culture conditions. The complications in the
utilization of hMSCs as therapeutic tools in vivo, arise due
to the experimental artefacts introduced by inconsistent cell
cultureprotocols.Thisnecessitatestheestablishment ofstan-
dardized culture guidelines for the isolation and expansion
of hMSCs that display minimal variability in their inher-
ent characteristic features (Table 1 [2–13]). Yet, laboratories
around the world lack an internationally standardized prac-
tice for in vitro expansion of hMSCs, resulting in heteroge-
neous populations of cells and inconsistent results, both in
in vitro studies and clinical trials.
(1) With Friedenstein et al. [14] demonstrating about 4
decades ago that ﬁbroblast-like cells grow from
bone marrow when plated on FBS (Foetal Bovine
Serum), animal sera remain the most ubiquitously
usedsupplementinMSCculturemedium.Despiteits
wide and prolonged use as an additive to chemically
deﬁned basal media for cell culture, FBS has its
own economical, ethical, and scientiﬁc setbacks.
This creates the necessity for the development of a
better alternative to FBS, which would overcome the
disadvantages.
This paper focuses on such prospective alternatives that
will guarantee the safe, economical, and ethical practice
of biomedical research, through the elimination of many
shortcomings of FBS. Furthermore, these FBS replacements
for hMSC culturing could ensure the passage of stem cell2 Stem Cells International
Table 1: Typical MSC characteristics (retention/loss) in various types of Media.
MSC characteristics Foetal bovine
serum
Chemically deﬁned
media Human serum Umbilical cord
blood serum
Human platelet
lysate (HPL)/
platelet-rich
plasma (PRP)
Adherence to plastic + +1 +2 ++
Morphology Spindle-shaped More
spindle-shaped
Smaller and more
spindle-shaped
Elongated and
more spindle-
shaped3
Elongated and
more spindle-
shaped (hPL).
Smaller cells in
PRP
Surface antigen expression
C D 1 0 5 +++++
C D 7 3 +++++
CD90∗ +++++
CD45 −−−−−
CD34 −−−−−
CD14/CD11b −−+/−4 NA −
CD79a/CD19 −−NA NA −
HLA-DR − +/−4 −−−
Tri-lineage
diﬀerentiation ++ 5 +6 +7 +
CFU-f eﬃciency Large and well
spread
Varies with media
components
Densely packed.
Mesh-like growth
pattern in later
passages
Densely packed
larger colonies3
Densely packed
(hPL and PRP)
Mesh-like growth
pattern in later
passages (PRP)
Doubling time 76–89 hrs ↓4 ↓↓↓
Cost and availability
Available from
certain countries,
∼500 to 800 USD
for 500ml.
Commercially
available, expensive
Available and
cheaper
Available and
cheaper
Available and
cheaper
References [3, 4][ 5, 6][ 4, 7–9][ 4, 10][ 7, 11–13]
∗Eﬀect on immunosuppressiveproperty of hMSC [2].
NA: data not available.
1When adhesion factors are added.
2Decreases in later passages.
3Author’s observation. Unpublished data.
4 Aﬀected by the factors added in the medium.
5Deﬁned media for each speciﬁc diﬀerentiation are available.
6Diﬀerentiation of hMSCs into osteoblasts was enhanced [4].
7Enhanced diﬀerentiation of hMSCs into osteogenic lineage and suppressedadipogenesis also seen [10]. No data available for chondrogenic diﬀerentiation in
UCBS-cultured MSCs.
research from bench to bedside, a safe and more realistic
vision.
2.Scientiﬁcand EthicalProblemswithUsageof
Animal Serum
The usageofFBSasa medium-supplementinhMSCcell cul-
tureiswidespread,despitethemanydisadvantagesassociated
with it. The scientiﬁc problems encountered in cell culture
due to the presence of FBS are batch-to-batch variability,
ﬂuctuating availability, unexpected cell growth characteris-
tics,cytotoxicityof uncharacterized factors in theserum, and
so forth. Another major caveat associated with the usage of
animal serum is the risk of possible contamination with vi-
ruses [15], prions, bacteria, nanobacteria [16], mycoplasma,
yeast,fungi,and endotoxins,someofwhich areimpossible to
remove from the serum. In addition, the presence of certain
general animal-serum components (that usually enhance
adhesion and spreading and occasionally inhibit cell growth)
in variable amounts, such as (1) immunoglobulins, (2)
t r a n s c r i p t i o nf a c t o r s( A T F - 2 ,S R E - Z B P ,G A T A - 2 ,T F I I D ,E t s -
1/Ets-2, E2F-1, Oct-2, p53, AP-2) [17], and (3) growth
factors (platelet-derived growth factor [18, 19], insulin-
like growth factors [20], epidermal growth factor [21, 22],
ﬁbroblast growth factor [23]n e r v eg r o w t hf a c t o r[ 24]), canStem Cells International 3
intervene with the cellular function, growth, and the pheno-
typic/genotypicstabilityoftheculturedcells[25].Additional
variability is introduced by thelarge number ofexperimental
variables induced by certain identiﬁed/unidentiﬁed compo-
nents in the serum [26, 27].
The immunogenicity of FBS-cultured cells has raised
many concerns for their use in therapeutic strategies, since
reports of anaphylactic or arthus-like immune reactions in
patients, following the infusion of lymphocytes grown in
FBS-media[28].However,clinicaltrials performed onnearly
2000patientshaveusedFBS-culturedhMSCs,andtherehave
been no reports on immediate signs of adverse eﬀects or
infusional toxicity [29]. Rare unfavorable occurrences and
late complications however may be identiﬁed only in large
groups of patients after long-time followup [30]. This may
be attributed to the transfer of approximately 7–30mg of
xenogeneic proteins (from FBS) per 108 hMSCs in culture
[31]. Thus, thorough evaluations of long-term patient
followups would give a more solid base for establishing
the total safety of novel hMSC therapies from a clinical
perspective. This potential risk renders the animal serum-
grown cells inapt for clinical applications, proving to be a
major roadblock in the passage of in vitro research ﬁndings
to therapy. In spite of these growing concerns, FBS-cultured
hMSCs have been approved by the US Food and Drug
Administration (FDA) for use in human clinical trials and
is widely being used in cell culture laboratories all over
the globe.
Scientiﬁc diﬃculties aside, another major downside of
FBS usage is the inhumane method of collection of blood
fromthefoetalcalves.Onanaverage,around1,000,000foetal
calvesare killed each year for collecting around 500,000litres
of FBS [25, 32]. This is on strikingly discrepant terms with
o n eo ft h em a j o ro b j e c t i v e so fm o d e r nin vitro biomedical
research, namely, the prevention/reduction in the usage of
animals for research and testing. On conﬂicting terms, usage
of FBS in cell culture does not help in “reducing, replacing,
and reﬁning” animal experimentation but instead asserts the
exact opposite of The Three R’s concept in scientiﬁc research
[33].
The methods adopted for harvesting blood from the
foetal calf are another issue of concern in the usage of FBS
in animal cell culture. The most common method of blood
collection is by cardiac puncture without anaesthesia, from
a still-beating foetal heart. The disturbing fact is that at
70% gestation age (around 6 months offoetal development),
which is most preferable for the blood collection, the calf is
reported to develop awareness to pain and distress [34]. A
thoroughanalysis by experts in the ﬁeld offoetal nociception
and awareness has shown that any undesirable response
from the foetus can be prevented by cutting the dam’s neck,
thereby inducing a sudden fall in the EEG/ECoG in the dam
as well as the foetus, almost simultaneously. The prevention
of oxygen intake by the lungs of the calf has been reported
to minimise awareness to pain [34]. Based on these studies,
several measures to minimise nociception and suﬀering of
the animals have been adopted during slaughter and foetal
blood harvesting. The safe guards of blood harvesting from
the foetus according to the workshop “Towards Better In
Vitro Methods, The Replacement of Foetal Bovine Serum”
held in April, 2003 in Utrecht, the Netherlands [35]a r ea s
follows.
(a) The blood collection must begin only after the
EEG/ECoG of the neck-cut dam becomes ﬂat and
stays ﬂat throughout the procedure.
(b) After separating the foetus from the mother, it must
not be allowed to breathe air at any time during the
procedure.
(c) The foetus must be stunned immediately if it is
allowed to breathe air after being removed from the
dam.
These safeguards only ensure that the calf is unconscious
and desensitized to the pain caused during the cardiac
puncture and blood collection. However, the number of
foetal calves which are sacriﬁced to meet the demands is too
high to be compromised.
With cell and tissue culture becoming an indispensable
tool in biomedical research, FBS-free culture techniques
would beneﬁt scientists in many aspects; by achieving a
conformity of the research to Good Cell Culture Practices,
it would make in vitro cell culture a more economical and
ethical practice.
3. Alternativesto Animal Serumin
StemCellCulture
Various animal serum alternatives have been tested for their
ability to sustain proliferation and diﬀerentiation of hMSCs
in the recent past. The major drawback, that withholds the
adaptation of FBS-free culture techniques for hMSC culture,
is the incapability of hMSCs to survive in the absence of
serum-speciﬁc growth factors as well as other unidentiﬁed
factors in the serum. In addition, serum not only functions
as a buﬀering agent [36]b u ta l s oo ﬀers protection against
certain “cytotoxic” agents by unknown mechanisms. Hence,
the choice of serum for the growth of hMSCs has a pro-
found eﬀect on the health and quality of the cells in culture
leading to a search for serum/suitable alternatives from
other sources, with FBS-like properties, but not of animal
origin.
Otherimportantqualitiesthatareexpectedofaneﬃcient
medium additive are
(i) consistency in the concentration of the constituents,
(ii) absence of contaminants,
(iii) low cost,
(iv) longer shelf-life,
(v) ready/easy availability.
Based on these features, the following alternatives have
beenproventobepotentialFBSreplacementsthatareequally
good, if not better suited for hMSC culture, with each alter-
native having its own set of advantages and disadvantages.4 Stem Cells International
3.1. Human Blood-Derived Alternatives. Human-derived
medium additives, that can replace FBS, have been investi-
gat edinthepas tc oupleofy ear sandha v eledt othedis c o v ery
of eﬃcient alternatives such as human serum—autologous
and allogeneic human serum albumin (HSA), thrombin-
activatedplateletreleasates(t-PR),collagen-activatedplatelet
releasates (c-PR), human platelet lysates (hPL), umbilical
cord blood serum (UCBS), and autologous plasma-derived
from bone marrow (APM) (Table 2 [37–47]). The major
advantageofthesehumangrowthsupplementsistheabsence
of any risk of secondary eﬀects which may be caused by
FBS constituents in culture. Nevertheless, the possibility
of contamination from adventitious agents in these blood-
derived substituents remains a threat, but it could, however,
be kept at bay by strict adherence to blood bank quality
standards. However, the risk of sensitization by blood group
substances or by pathogens not covered by routine blood
donor testing poses another major risk in the usage of
such products. Therefore, the need for implementation of
various strategies to deal with these shortcomings seems
inevitable. Filtration through pores of 0.2μm though would
serve to eliminate certain bacteria and particulate matter
would be ineﬀective in the removal of viruses, usually less
than 0.1μm in size. Recently researchers at the Fraunhofer
Institute for Mechanics of Materials IWM in Halle, Germany
havedevelopedhigh-precision nanoporousﬁltermembranes
of aluminium oxide with pore diameters ranging from
15nm to 450nm, where the removal of even the smallest
viruses could be achieved [48]. Other pathogen inactivation
procedures like photochemical treatment with amotosalen
and ultraviolet-A light have proven eﬀective in ensuring the
highest possible quality standards [49].
High variability among human blood samples could also
produce inconsistencies in hMSC growth. This could be
addressed by pooling a number of individual prescreened
samples, which however does not appear feasible and lacks
economy of scale from a research standpoint, particularly
with the rigorous quality control strategies for a large
number of samples. Nonetheless, these growth supplements
can function as eﬃcacious alternatives for in vitro hMSC
expansion in the research laboratory, till commercial ready-
to-use chemical medium formulations become accessible.
3.1.1. HumanSerum. Studieson hMSCisolation and expan-
sion in 10% human autologous serum (HAS) (without any
cytokines or growth factors) have proved that it is equivalent
to 10% FBS in stimulating growth, making it an eﬀective
FBS alternative that is safe for therapy [9, 50, 51]. One
study reported a novel method of collecting HAS in a closed
bag system, thereby decreasing any risk of virus or bacterial
infection and foreign protein contamination of the cultured
cells [52]. Another study, conducted on the use of HAS in
culture and transplant of MSCs in cellular cardiomyoplasty,
has reported prevention of life-threatening arrhythmias,
thereby highlighting HAS as a promising candidate for FBS
replacement [53]. These evidences strongly support substi-
tutionofHASinthe place ofFBSasa growth supplementfor
hMSCs growth and expansion.
HAS-cultured mesenchymal stem cells remain morpho-
logically similar to FBS-grown hMSCs and had signiﬁcantly
shorter population doubling times, in the range of 41–54
hours, when compared to 76–89 hours in FBS media [9].
Contradictory results were observed in the use of allogeneic
serum for hMSC culture, where the cells took longer to
adhere and proliferate and never reached 60% conﬂuence
[31]. This hints at the presence of some allogeneic factors in
the human serum that have an inhibitory eﬀect on hMSC
growth and survival, which is not exhibited by cells grown
in FBS-supplementedmedia despite the xenogeneicorigin of
FBS.
Gene expression studies on HAS-cultured hMSCs
showed diminished diﬀerentiation capability and high pro-
liferation rates, due to the increased expression of factors
like angiopoietin-like 4 gene (apoptosis inhibiting role) [9,
54]. On the other hand, cells grown in FBS media exhibit
an upregulation of both the cell cycle and diﬀerentiation
genes tuning them on for diﬀerentiation into osteocytes,
adipocytes, and chondrocytes [9]. FBS-cultured MSCs also
had several prostaglandin-synthase genes upregulated, mak-
ing them favourable for use in studies that exploit the
immunosuppressive properties of MSCs [9]. Nevertheless,
cells cultured in HAS exhibit transcriptome stability over a
long time, but a major concern regarding their use in the
clinical scenario is the limited availability. A strategy that
couldovercomethisdisadvantage istheadaptationofculture
conditions that are speciﬁc to the clinical requirement. For
instance,inbonereconstruction,where therecouldbealimit
tothenumberofprogenitorsrequired,HASseemsofinterest
as it favours osteoblast diﬀerentiation [55].
Pooled human AB serum has also been proven to be
a feasible alternative to FBS, supporting the proliferative
and diﬀerentiative ability of hMSCs in addition to retention
of the MSC characteristics throughout ex vivo expansion
culture [7]. There have been reports of successful isolation
and expansion of bone marrow-derived MSCs using AB
serum though growth arrest had been reported after the
ﬁrst passage [9, 31, 56, 57] .A d i p o s et i s s u eM S C sh a v eb e e n
eﬃciently grown in long-term culture with AB serum with
similar cumulative population doubling as FBS [7]. These
observations remain to be thoroughly evaluated from a
clinical perspective before labeling pooled AB serum as an
ideal FBS substitute.
There has been an interesting report on the eﬃcacy of
human AB serum/human autologous plasma in minimal
quantities combined with a new serum substitute con-
taining vegetable-derived proteins in the culture of MSCs.
The growth and diﬀerentiation characteristics remained
unchanged in the new combination media displaying its
synergistic eﬀects on CFU-F formation [57]. Thus, such
assertions validate the need for further research into the
method of using low concentrations of serum that may limit
cell proliferation but still be suﬃcient for therapeutic appli-
cations.
3.1.2. Allogenic Umbilical Cord Blood Serum. For decades
now, human umbilical cord blood has been viewed onlyStem Cells International 5
Table 2: Comparison between the general components of serum and human platelet lysate and their eﬀect on hMSC culture.
Components that play a major role in cell
culture
Human
Platelet
Lysate
Human
Serum∗
Umbilical
Cord Blood
Serum∗
Eﬀects in hMSC Culture
High abundant proteins
(i) Albumin − + + Major binding protein [40]
(ii) Transferrin − + + Iron transporter [41]
(iii) Fibronectin − + + Cell Adhesion and Migration [42]
Growth factors and cytokines
(i) Epidermal growth factor (EGF) + + + Proliferation and diﬀerentiation
(ii) Fibroblast growth factor (FGF) − +1 +2 Proliferation,diﬀerentiation, and
migration
(iii) Nerve growth factor (NGF) − + + Regulation of apoptosis
(iv) Vascular endothelial cell growth
factor (VEGF) +3 +1 +2 Proliferation and migration
(v) Platelet-derived growth factor
(PDGF) +3 + + Proliferation and migration
(vi) Insulin-like growth factors (IGFs) +3 + + Proliferation and migration
(vii) Transforminggrowth factors (TGFs) +3 + + Proliferation4 and cell-cell adhesion
(viii) Interleukins + + + Maintenance of stemness
( i x ) I n t e r f e r o n s +++ Diﬀerentiation and MHC antigen
regulation
References [37, 38][ 39][ 39][ 36, 37, 43–46]
1Released as a result of injury in the body.
2May be found due to its role in foetal development.
3Found in higher concentrations.
4Higher concentrations inhibit cell proliferation.
∗The components of the serum have been identiﬁed but have not been characterized. Protein precursors required for maintainingfoetal conditions are found
only in umbilical cord blood serum [47]. The top 5 abundant proteins present in UCBS and their molecular functions are listed in Table 3.
as a source of hematopoietic stem cells, for transplantation
in the treatment of various blood-related disorders and
malignancies in both adult and children. The notion of
using human umbilical cord blood serum (hUCBS) as a
supplement for hMSC culture stemmed from the fact that
cord blood is a rich source of soluble growth factors that
support the growth, proliferation, and diﬀerentiation of the
resident stem cell population in the foetal blood [58]. Cord
blood imparts distinct characteristics to the cord blood-
derived stem cells that bone marrow-derived cells do not
exhibit [59], and this feature could present a unique micro
environmentthatcouldsupporttheexvivocultureofhMSCs
and other mammalian cell lines. In a study conducted by
Bhattacharya et al. [60], it was proven that hUCBS could
be used as a serum replacement for FBS in the culture of a
number of mammalian cell lines.
Human bone marrow-derived MSCs are highly prolif-
erative cells requiring a culture medium that contains a
cocktail of growth factors and proteins for their in vitro
g r o w t ha n ds u r v i v a l .T h ep r e s e n c eo fp r o t e i n sl i k es e r u m
albumin and transferrin in high abundance is one of the
reasons why hUCBS is suitable for cell culture [47]. Human
serum albumin binds to several small molecules and acts
as an antioxidant in most cases. The binding results in the
regulation of a range of processes, such as apoptosis (nega-
tive regulation), distribution of cellular components, cellular
response to starvation, chaperone binding, and transport of
molecules in and out of the cells, that play vital roles
in cell growth and proliferation [61]. Transferrin, on the
other hand, is an iron-transporting protein that directly
regulates cell growth by modulating the cell cycle at S
phase [41, 62]. Higher concentration of transferrin is thus
required for culture of proliferating cells than cells which
are diﬀerentiating. The intake of transferrin is governed by
the regulation of the transferrin receptors on the cell surface
[63–65]. Apart from the proteins commonly present in the
serum, 61 proteins speciﬁc in neonates have been identiﬁed
in hUCBS [47]. The enhanced growth and proliferation of
the hMSCs in UCBS may be due to these proteins, although
their exact eﬀect on hMSC culture is unknown. Protein
precursors abundant in UCBS and their possible functions
in in vitro MSC culture are listed in Table 3 [47, 66].
Cells cultured in 10% hUCBS-supplemented media have
shown exponential growth with a doubling time of only
31.3 hours, compared to a longer doubling time of 44.2
hours in 10% FBS-supplemented media [10]. The enhanced
growth exhibited by hMSCs in hUCBS medium, (a 32-fold
increase in cell number after just 5 days of seeding (10-fold
increase in 10% FBS-supplemented media)) [58], has been
reported to be due to the high level of expression of cyclin
D2, the cell cycle regulatory molecule which enhances the
cell-cyclingactivitiesinhMSCs[10].Anincreased expression6 Stem Cells International
Table 3: Protein precursors abundant in UCBS and their possible functions in in vitro MSC-culture.
S. no. Protein precursor In Vitro eﬀects on hMSCs
(1) Alpha-2-macroglobulin precursor (i) Natural protease inhibitor
(ii) Role in cell regulation and diﬀerentiation
(2) Apolipoprotein B-100 precursor (i) Cholesterol transporter activity,
(3) Complement C3 precursor
(i) Positive regulation of VEGF production
(ii) G-protein coupled receptor protein signaling pathway
(iii) Natural protease inhibitor
(4) Complement C5 precursor
(i) Chemotaxis, positive regulation of VEGF production
(ii) Natural protease inhibitor
(iii) G-protein coupled receptor protein signalingpathway
(iv) Positive regulation of chemokine production
(5) Isoform 1 of complement factor H precursor (i) Negative regulation of complement C3
of the embryonic pluripotency gene, Oct-4, in these hMSCs
couldbe related tothe high proliferationrates, in consistence
with previous reports of high Oct-4 expression levels in
proliferating hMSCs [67, 68]. It was also found that certain
h U C B Sp r o t e i n sw i t hm o l e c u l a rw e i g h t sg r e a t e rt h a n1 0k D a
had growth-enhancing eﬀects on the hMSCs [10].
Cells grown in hUCBS-supplemented media retained
their self-renewal capacity and sustained replicative poten-
tial, allowing nearly a 2000-fold expansion of the cells
[10, 58], in contrast with FBS-cultured hMSCs that lose
their colony-forming property at later passages and exhibit
senescence early during in vitro expansion [69].
Electron microscopic analysis of hMSCs, grown in
hUCBS, reveals some phenotypic diﬀerences at the cellular
structure-level including a smaller size, a denser nuclear
membrane, and meager cytoplasm as compared to FBS
grown cells [10]. Nevertheless, the hUCBS-grown hMSCs
hold their characteristic surface marker expression (HLA-
DR, CD73, CD90, CD34, CD45, CD166, and CD105), de-
spite their diﬀerencesin structure, self-renewal, and prolifer-
ative capacities [10, 58].
One of the unique features of hMSCs is its multipotent
nature, or, in other words, its ability to diﬀerentiate into
morethanonelineage.Variousstudieshaveshown thatwhile
the adipogenic diﬀerentiation potential of hMSCs grown
in hUCBS medium is retained, the cells exhibit stunted
adipogenesis, showing a threefold decrease in the number
of oil red positive adipocytes in comparison with FBS-
hMSCs [58]. On the other hand, the cells showed a more
heightened osteogenic diﬀerentiation potential, owing to
certain unknown stimulatory factors present in hUCBS [10].
The cells exhibited a substantial basal level of expression
of osteopontin, osteocalcin, and alkaline phosphatase in the
proliferative phase of growth in the hUCBS-grown hMSCs,
unlikeFBS-grownhMSCs where these proteins are expressed
only during diﬀerentiation. Thus, hMSCs in hUCBS had
ap r o p e n s i t yt od i ﬀerentiate into osteocytes due to high
expression of osteocalcin promoter, making them biased
towardsanosteogeniclineage[10].Thisexceptionaldiﬀeren-
tiation pattern was consistently observed in diﬀerent batches
of hMSCs, proving the fact that the unique stimulatory
eﬀects on the hMSCs are from certain proteins in hUCBS
and not because of atypical behavior displayed by diﬀerent
subpopulations of hMSCs [10].
The variability in the diﬀerentiation patterns of hUCBS-
grown hMSCs, induced by unidentiﬁed factors in hUCBS,
brings about the necessity to test the eﬃcacy of the supple-
ment for the transdiﬀerentiation of hMSCs into hepatocyte,
cardiomyocyte, or neuronal lineages. hMSCs grown in
hUCBS-supplemented media also retain the ability to diﬀer-
entiateinto ahepatocyticlineagewith an enhancedeﬃciency
(Sankaranarayanan K. et al. (manuscript communicated and
under review)).
Apart from being an abundantly-available allogenic
serum source, hUCBS has the added advantage of being free
of xenogenic contaminants making the cells expanded in
hUCBS-supplemented medium of therapeutic quality. The
relatively easy and inexpensive isolation procedure followed
to obtain clinical-grade cord serum from umbilical cord
blood is one among the various advantages of using hUCBS
as a medium additive. hUCBS has been extensively inves-
tigated as a safe, highly potential, and stable replacement
for FBS, as it economically and ethically overcomes the
shortcomings of FBS. However, the drawbacks of hUCBS are
numerous: an ill-deﬁned serum acts as an ambiguous factor;
lot-to-lot variability and presence of adventitious agents that
may have escaped routine screening procedurespose a threat
to the purity of cells in culture. Even so, UCBS could prove
to be useful as a temporary replacement for FBS until a
more deﬁned culture medium is identiﬁed for the culture of
hMSCs.
3.1.3. Human Platelet Derivatives. Extensive research has
been conducted on human serum-free alternatives such
as thrombin-activated platelet releasates (t-PR), collagen-
activated platelet releasates (c-PR) and human platelet lysate
(hPL). Recent studies have indicated that they could be
potential FBS replacements in cell culture and could support
the growth and viability of a number of diﬀerent animal cell
lines [70].
Plateletsorthrombocytesarecolorless,irregularly shaped
nonnucleated bodies, released in blood by the fragmentation
of megakaryocytes. In a healthy adult, the concentration
of platelets ranges from 150,000 to 400,000 platelets perStem Cells International 7
microliter. In vivo, these platelets play a major role in hae-
mostasis, assisting in the formation of blood clots and blood
vessels [71] and in wound healing after injury. This wound
healing property of platelets is of major interest as it
involves the release of multifarious growth factors like
platelet-derived growth factor, transforming growth factor-β
(TGF-β), ﬁbroblast growth factor (FGF), insulin-like growth
factor-1 (IGF-1), platelet-derived epidermal growth factor
(EGF), vascular endothelial growth factor (VEGF), platelet
factor-4 (PF-4), attachment factors (ﬁbronectin and vit-
ronectin), coagulation factors, mitogens, protease inhibitors,
proteoglycans, and serotonin, that help in recruiting stem
cells to the site of injury, thus stimulating diﬀerentiation
and angiogenesis, which are critical in tissue healing [72–
78]. This property of platelets, especially the presence of
concentratedpoolsofthe bioactivemoleculeslikePDGF-α/β
and TGF-β, is exploited for its use as a substitute for FBS in
cell culture.
Platelet lysate is generally prepared from platelet-rich
plasma (PRP) isolated from uncoagulated blood (commonly
used anticoagulant is Citrate). The preparation of these
platelet releseates/lysates is done either by mechanical dis-
ruption or chemical lysis of the platelet membrane. The
chemical lysis is carried out by the addition of Ca2+,
collagen, or bovine thrombin to the isolated plateletsthereby
activating the clotting cascade. The coagulated ﬁbrinogen is
then separated from the liquid suspension, containing the
platelet lysate, by centrifugation and microﬁltration. The
most commonly used mechanical method involves repeated
freeze/thawcycles(freezing at −20◦Candtha wingat<37◦C),
thereby disrupting the platelets through ice crystal forma-
tion. The mechanical method of platelet lysis is preferred
over the chemical lysis methods due to its simplicity and
cost-eﬀectiveness. Additionally, this method eliminates the
necessity for any expensive puriﬁcation procedure to remove
the added factors, like calcium, thrombin, or collagen, from
the lysate.
Platelet lysate also has been shown to support the growth
of hybridoma cells and even enhance proliferation in a
variety of tumour cell lines, transformed animal cell lines
such as 3T3, SV3T3 and mouse ﬁbroblast [79]a n dh u m a n
endothelial cells [80]. Subcellular fractions of these platelets
also have a signiﬁcant positive eﬀectonthe culture ofhuman
ﬁbroblast-like cells [81], promoting cell adhesion, prolifera-
tion, diﬀerentiation, and cell survival, thus contributing to
the increase in cell adhesion, CFU-f size, and a decrease in
the time taken to reach conﬂuence [12]. It has also been
reported that the usage of human platelet lysate (hPL) in
hMSC culture resulted in enhanced proliferation of the cells
without any alteration of their diﬀerentiation capabilities,
thereby making hPL a possible candidate for in vitro stem
cell culture for regenerative medicine [80].
A recent study has demonstrated that hMSCs display a
more elongated, spindle-shaped morphology when cultured
in hPL, thus having more number of cells per growth area
[38]. The cells proliferate signiﬁcantly faster in hPL media,
reaching P4 in only 60 days as compared to ∼100 days when
cultured in FBS media [12]. This enhanced growth in hPL is
attributed to diﬀerential gene expression proﬁles, inducedby
these growthfactorsinthehMSCsincludinganupregulation
of cell cycle and DNA replication proteins and the down-
regulation of attachment, development, diﬀerentiation and
apoptotic genes [82].
hPL-grown MSCsalsoretain theirmultilineagepotential,
being still able to eﬃciently diﬀerentiate into osteocytes,
chondrocytes, or adipocytes when subject to appropriate
induction conditions [12]. However, there has been a report
indicating weakdiﬀerentiationofprimary culturesofhuman
musclecellsintomyotubeswhenculturedinhPLmedia.This
could indicate that certain unidentiﬁed factors in FBS, that
are absent in hPL, may have a positive inﬂuence on primary
human skeletal muscle cell culture [83].
An important property of hMSCs is their immunomod-
ulatory function [38], impairing T-cell activation and, as a
result, lowering the immune response after transplantation.
The lack of expression of MHC II complexes on the surface
of hMSCs is the reason for the lowered immune-stimulation
capability of in vitro expanded hMSCs. It has been reported
that these properties of hMSCs remain unaltered when
g r o w ni nh P L[ 38], making them more favourable for allo-
geneic transplants, reducing possibilities of graft rejection
and life-threatening graft-versus-host disease (GVHD).
The use of hPL seems a ﬁrst step towards a deﬁned
serum-free MSC expansion procedure; however, hPL prepa-
rations may also have donor-to-donor variations, making it
diﬃcult to standardize culture conditions. In spite of these
conditions, hPL remains the most eﬃcient FBS replacement
f o rl a r g e - s c a l ee x p a n s i o nw h e nc o m p a r e dw i t ho t h e rc u r -
rently available human blood-derived alternatives [84]. In
the clinical setting too, hPL could be autologously derived
from the patient and be used safely for cultivating hMSCs
for transplantation, reducing the patients’ exposure to xeno-
geneic/allogeniccompoundsand subsequentimmunological
reactions. Studies on hMSC growth and diﬀerentiation
capabilities using hPL have shown promising results, being
safe also for reinfusion into patients [11, 84, 85].
3.2. Chemically Deﬁned Media. Chemically deﬁned serum-
free media, supplemented with essential growth factors and
nutrients to support the growth of hMSCs in vitro,w e r e
developed in an attempt to culture cells in the absence
of animal serum. This accounts for a more controlled,
consistent environment for cell growth, but few eﬀorts were
made to adapt the existing cell lines to serum-free media,
resultinginthecontinuedpracticeofculturingmostcelllines
with FBS-supplemented media.
Unlike serum that contains a cocktail of growth factors,
attachment factors, buﬀering agents, detoxifying agents,
and compounds of varied molecular weight, a chemically-
deﬁned medium must provide these factors individually, at
precise concentrations, to bring about eﬀective proliferation
without altering the cell’s phenotypic characteristics. A
serum alternative should suﬃciently mimic the properties
of the serum in culture. Essentially, all of the human-
derived alternatives discussed above have the ability to both
promote the adhesion of the hMSCsspeciﬁcally and produce
a signiﬁcant enhancement in the growth rate of the cells,8 Stem Cells International
during ex vivo expansion. Thus, in the design of an ideal
serum-free chemicallydeﬁnedmediumforMSCculture,two
major factors are to be considered:
(1) ability of the serum-free medium to selectively
promote the adhesion of MSCs and generate CFU-
fs in the primary passage, completely excluding other
contaminating cells from the culture dish,
(2) speciﬁcally support and enhance ex vivo expansion
of MSCs, without altering their inherent cellular
characteristics orpermitting the cellstoenteran early
replicative senescence.
Generally,chemicallydeﬁnedmediaaremadeusingbasal
culture media such as DMEM α-MEM, onto which the
required components are selectively added depending on the
type of cells cultured. The selection of the additives and
their concentrations, especially the growth factors, is very
critical since it could variably aﬀect the cells cultured. For
example, increased level of b-FGF in the media heightens the
aﬃnity of hMSCs towards osteogenic diﬀerentiation [86]. A
ﬁne example of cytokine-inﬂuenced variations in cell growth
is observed in hMSCs cultured in a serum-free medium
containing FGF, PDGF, and TGF-β.A l t h o u g hT G F - β does
not play a signiﬁcant role in cell proliferation [5], only the
synergistic eﬀect of all these three growth factors results in
better growth and survival of hMSCs [87].
Apart from growth factors, attachment and spreading
factors are important for the proliferation of adherent cells
in the culture. Fibronectin is a commonly used attachment
factor that can be coated on the culture surface or added
to the medium as a supplement. Other cost-eﬀective and
eﬃcient methods of increasing the cell adherence include
coating the surface with gelatin, alginate, or nanoscaﬀolds
[88, 89]. Serum albumin is the most commonly added
protein, which transports lipoproteins into the cell and
also provides a buﬀering eﬀect in the medium, followed
by transferrin, an ion transporter. Hormones essential for
the growth of the cells are also added in appropriate
concentrations in the chemically deﬁned media. Growth
hormones, such as hydrocortisone, are added to the medium
in the long-term culture of hMSCs.
Certain minerals and other molecules which act as co-
factors for numerous cellular pathways are also required
as additives in chemically deﬁned media for the in vitro
culture of cells. These trace elements possess various enzyme
binding properties and regulate speciﬁc gene expression
leading to alterations in the cell division and diﬀerentiation
[90]. Biotin, ethanolamine, and trace elements like selenium
and iron are also routinely added in hMSC culture media.
Ingeneral,chemically deﬁnedmedia forculturingadher-
ent cell lines such as hMSCs contain albumin, growth fac-
tors, attachment factors, hormones, lipoproteins, and trace
elements. A broad range of serum-free, xeno-free chemically
deﬁned media (STEMPRO MSC SFM, from Invitrogen,
Carlsbad, CA; MesenCult-ACF Culture Kit (for optimal
cell adherence) and MesenCult-XF Culture Kit (expan-
sion medium) from STEMCELL Technologies, Vancouver,
Canada) for hMSC culture are available commercially [39].
These commercially available media claim to be able to
maintain the basic characteristics of MSCs while sustaining
diﬀerentiation potentials and colony formation potentials
and also exhibiting superior proliferation potentials [91].
Serum-free media containing growth factors like FGF-2, LIF,
SCF, and other supplements such as pantothenate, biotin,
and selenium have also been reported to support enhanced
proliferation of hMSCs in vitro [92].
hMSCsculturedinchemicallydeﬁnedmediadisplaynor-
mal features even with higher growth rate, although obser-
vation of smaller cell structures and non-traditional growth
pattern is common after repeated passages [5]. The desirable
qualities of these chemically-deﬁned media, apart from
the ethical advantage over FBS, are their precise chemical
composition, the absence of microorganisms and hard-to-
remove“contaminants”likeimmunoglobulins,thusfacilitat-
ing acontrolled environment fortheselective growthofcells.
Chemically deﬁned media are designed to achieve spe-
ciﬁc eﬀects on the cells including high proliferation rates,
diﬀerentiation into speciﬁc cell types, and so forth, by
varying the additives and its concentrations. A thorough
analysis of the variations in the composition of these media
is needed to developa chemically deﬁned mediumfor hMSC
culture. The optimal media constitution mainly depends on
the requirements of individual experimental conditions and
may vary largely between and within cell types. This is one
of the major obstacles in designing a standard chemically
deﬁned medium common for hMSC cell culture. Estimation
of the exact quantities of cytokines required by the cells to
suﬃciently prolong the proliferative age of the hMSCs ex
vivo, is a highly tedious process complicated by the poorly
understood eﬀects of individual growth factors on hMSC
culture. This could result in changes in the inherent hMSC
properties, such as HLA-DR surface antigen expression by
FGF-2 and PDGF-ββ [93]w h i c hm a yi nt u r nb r i n ga b o u t
undesired eﬀects after transplantation. Moreover, with the
compositions of the currently available synthetic media
remaining as intellectual properties of the manufacturers,
the prices remain relatively high (when compared to the
humanized alternatives). On the other hand, these chemi-
cally deﬁned media seem to be safer for clinical settings, in
spite of the fact that not all the reagents and factors used are
clinical-grade. This could best be overcome by synthesizing
the cytokines as clinical-grade recombinant proteins on a
large scale, while at the same time optimizing the economy
of production of these therapeutic-quality reagents.
4.ExtracellularMatrixComponents
hMSCs cultured in vitro also express surface antigens like
CD144, CD166, CD115, CD29, HLA-ABC, Sca-1, and Stro-
1, other than the ones mentioned by Dominici et al.
[3]. However, no available marker can be reliably used to
conﬁrm the purity of these cultured MSCs, and, hence, some
experts argue that these “MSCs” represent a heterogeneous
population of multipotent cells in which the real “stem-cell”
component is limited [94]. Consequently, there have been
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can closely mimic its in vivo cellular niche, which is believed
to supply critical biochemical and physical signals to initiate
and sustain cellular functions. Bone marrow-derived hMSCs
have been reported to exhibit signiﬁcantly reduced cellular
aging, increased proliferation capacity, and retention of
diﬀerentiation potentials when maintained in vitro on dena-
tured collagen matrices [95]. The preservation of adipocytic
markers and functions and the osteogenic diﬀerentiation
potential of hMSCs expanded on denatured collagen type
Im a t r i x[ 96, 97] further underpin the signiﬁcance of the
matrix-mediated eﬀects on hMSC culture. Murine MSCs
have been eﬃciently expanded in conditions that simulate
aninvivobonemarrow ECMmicroenvironment. This paper,
utilizinganECMcomponentmadefromcollagentypesI,III,
and V, syndecan-1, perlecan, ﬁbronectin, laminin, biglycan,
and decorin, emphasizes the vital role played by the bone
marrow ECM in maintaining the “stemness” of MSCs [98].
Three-dimensional stem cell culture with synthetic
hydrogel networks made of polyethylene glycol (PEG) or
polyethylene glycolfumarate have also proven eﬃcient in the
maintenanceofhMSCsexvivo,thusdemonstratingimmense
applications in a range of tissue engineering applications.
Hydrolytically degradable PEG hydrogels, constructed via
sequential step growth polymerization and photocross-
linking processes, have numerous applications in “3D stem
cell culture.” The PEG hydrogels remain unable to support
adhesion of hMSCs, as their resistance to protein adsorption
preventsthe cell adhesion molecules of hMSCs from binding
to the matrix.
Adhesion and spreading of hMSCs on these synthetic
PEG networks have been enhanced by incorporation of
a photoreactive, phosphate-containing molecule ethylene
glycol methacrylate phosphate (EGMP) [99]. Other unique
moleculessuch ascell adhesionligands derivedfrom laminin
and ﬁbronectin have been tested for their individual and
combined eﬀects on hMSC spreading and viability in
degradable and nondegradable PEG hydrogels, achieving
promising results [100]. Similarly, the eﬀects of FGF-2 on
the viability and spreading of hMSCs cultured in 3D PEG
hydrogel arrays were found to be improved when performed
under varying combinations of culture parameters such as
hydrogel matrix degradability, cell adhesion ligand type,
and density [101]. Therefore, such alternative approaches
to expanding hMSCs, guaranteeing the retention of unique
characteristics, represent a novel culture technique for pro-
ducing functional progenitors for various tissue engineering
applications. When coupled with the serum-free or xeno-
free culture conditions discussed earlier, these techniques
couldsignify arelativelysafe cellularregenerativetherapeutic
procedure for use in patients.
5.StrategiesforCultureMediumOptimization
Statistical design of experiments is a commonly used meth-
odology to optimize in vitro culture conditions for a wide
variety of growth systems, ranging from bacterial to animal
cell culture models. Such mathematical tools for the opti-
mization of culture media are highly warranted for, owing
to the lack of customization of experimental variables to ﬁt
every designed experiment. In the absence of ﬁne-tuning
of every media constituent in a medium, used for diﬀerent
experimentalpurposes,onlyaverycrudecontrolofthecellu-
lar and metabolic functions involvedin cell maintenance and
expansion is achieved, resulting in minimal experimental
success.
To overcome the drawback of excessive time consump-
tion of the one-variable-at-a-time method for optimization
of medium components, a multivariate analysis (MVA) is
followed. In MVA, one or more components are varied at a
time in the cell culture medium and their resultant eﬀects
on cell growth are estimated and correlated simultaneously.
Design ofexperiment (DoE)approach isagenerallyfollowed
methodology, in which various randomized or sequential
experiments are conducted to obtain statistical data for
betterselectionofthemediumcomponentsandtoaccurately
deduce their quantitative composition in the medium. This
method has proved successful for the optimization of media
components [102].
In DoE, the ﬁrst step is the selection of the compo-
nents/medium factors, whose eﬀects on the hMSCs are to be
studied. These factors are either chosen randomly or in an
order, based on the knowledge and experience gained from
studiesconductedearlierontheireﬀectsonhMSCexpansion
and diﬀerentiation. Such important variables, that have an
impact on the growth and metabolic activities of hMSCs,
can be isolated by fractional factorial design (FFD), in which
only a fraction of all the possible sets of factor variables
aﬀecting the culture are considered. By this method, a large
number of components can be analyzed by performing
2x−1experiments, where x is the number of variables, from
which a subset of factors having a major eﬀecton the hMSCs
can be separated.
After the critical components are identiﬁed by the
FFD experimental methodology, the concentrations of these
factors in the media are optimized. To predict the optimal
concentration of these factors to be added in the media, a
complicated experimental design is followed, so as to min-
imize the number of experiments conducted. Methods like
central composite design (CCD), method of steepest ascent.
are used to achieve thisresult. Two typesof CCDscommonly
utilized are central composite face-centered design (CCF)
and central composite circumscribed design (CCC).
A major feature here is the interaction between these
factors and their collective eﬀect on the cells in culture. This
is harder to estimate because the cells may be inﬂuenced
diﬀerentially at variable concentrations of the components.
Thus, to analyze the eﬀects of these protein factors on the
cells and on each other, contour plots and response surfaces
are used to clearly visualize the optimum value. In this
method, one or more explanatory variables are considered
and their eﬀects on the response variables (whose outcome
will be aﬀected by the explanatory variables) are analyzed by
varying the composition of the explanatory variables [103].
To ensure high reproducibilityoftheresults, the experiments
are generally performed in duplicates or triplicates. This
mathematicalandstatisticaltechniqueforoptimizingculture
conditions is termed the response surface methodology.10 Stem Cells International
A large number of statistical analysis tools are available
that can be used to reduce the labour involved in the cor-
relation of the results. This method has been adopted by
many researchers globally to design an optimum media
for cell culture. Liu et al. portray a good example of
the practical application of these statistical methods for
the optimization of serum-free medium for the ex vivo
expansion and diﬀerentiation of hMSCs [104]. The study
combines FFD and steepest ascent approach to successfully
design a serum-free medium for the culture of umbilical
cord blood-derived hMSCs. The trilineage diﬀerentiation
potential of these hMSCs in the newly optimized culture
medium remained unaﬀected thereby proving its eﬃcacy.
The optimal serum-free medium thus designed contained
human serum albumin, SITE (commercially available prepa-
ration containing speciﬁc concentrations of sodium selenite,
bovine insulin, human transferring, and ethanolamine), b-
FGF, and Hydrocortisone in the basal IMDM medium.
Though the physiological eﬀectiveness of this serum-free
medium has been proved by the growth of cord blood-
derived hMSCs, it however could not support the isolation
and expansion of hMSC coloniesfrom any other source such
as bone marrow, cord tissue, Wharton Jelly. This could be
primarily because of the facts that
(1) diﬀerent physiological states of hMSCs from varied
origins will warrant for diﬀerent active ingredients in
their culture medium,
(2) extrinsic factors like inherent diﬀerences in the
culture conditions and the experimental protocols
conventionally followed for hMSCs from varied
sources(mediumcomposition,pH,passageintervals,
etc.)
The variations in the hMSC diﬀerentiation and surface-
marker expression due to diﬀerences in their in vivo stem
cell niche [105, 106]m a ya l s oa ﬀect the reproducibility
of the optimum medium conditions identiﬁed. This high
degree of variability in culture medium requirements for the
same cell type from diﬀerent sources makesthe development
of a generalized optimal serum-free medium for clinical-
grade expansion highly challenging. Although no serious
ﬂaws have been detected in this methodology, the major
obstacle in the optimization of a perfectly deﬁned culture
condition is the limited data available on the eﬀects of all
the speciﬁc growth factors on hMSCs both in vitro and in
vivo. The ability to support the isolation, expansion, and
diﬀerentiation of hMSCs from diﬀerent sources should also
be taken into account while developing a new medium, so as
to obtain a generalized medium with speciﬁc components at
an optimum level.
6.Conclusions
The therapeutic dosage of hMSCs commonly employed for
infusion (e.g., in the treatment of graft-versus-host disease)
is >2 × 106/kg body weight of the patient [107]. Taken
together with the extremely low frequency of occurrence
of hMSCs in the human bone marrow (0.001 to 0.01%),
the ex-vivo expansion of hMSCs for therapeutic applications
is a must. Unfortunately, the lack of uniformity in the in
vitro hMSC-expansion protocols presents more challenges
in its ingression into the next phase in clinical research
and cell-based therapy. Variables introduced during long-
term ex vivo cell culture might have implications on the
fate of hMSCs, like the heterogeneity of subpopulations of
expanded cells, the disparity in expansion of the particular
subsets of the populations resulting in entirely diﬀerent
potentials of the end products [108]. Such irregularities,
where MSC properties could be modiﬁed or lost during
expansion, will thus have implications on the therapeutic
eﬃcacy of hMSCs grown.
Currently,most reported MSC-basedcellulartherapeutic
strategies utilize hMSCs expanded in FBS-supplemented
culture medium and none have reported any signiﬁcant
side eﬀects due to the presence of xenogenic proteins [55,
109]. On the contrary, FBS exhibits a neuro protective
function, mediated through the action of low-molecular-
weight bioactive factors (like serofendic acid), which help
in abolishing cytotoxic eﬀects induced by apoptotic and
necrotic signals [110]. Most regulatory agencies tolerate the
presence of xenogenic components in hMSC culture media
in phase I clinical trials, but later-phase studies and clinical
therapies would strictly require serum-free or at least xeno-
free media. Although, sequential cultivation of FBS-grown
MSCs in autologous or heterologous serum can remove up
to 99.99% of the xenogenic proteins [31], a residual risk still
remains.
The selection of the best replacement for FBS is crucial
and depends on its ability to obtain hMSCs with char-
acteristics similar to those of native MSCs. Consequently,
this would involve identifying the progenitors in fresh bone
marrow and evaluating their self-renewal and diﬀerentiation
capacities with the right tools under diﬀerent conditions
[55, 111].
Some recent protocols have tried to completely shun
FBS usage and shift focus towards “humanized” alternatives
such as autologous serum, allogenic umbilical cord blood
serum, or platelet extracts. Such changes in medium con-
ditions might inﬂuence immunophenotypic, genotypic, and
functional characteristics of hMSCs and thus warrant for
extensive studies into the cell-biological aspects of the cells
in diﬀerent growth supplements. In addition, a thorough
proteomic characterization of these humanized alternatives
wouldaidintheidentiﬁcationofthespeciﬁcfactorsthathave
in vitro growth-promoting eﬀects on hMSCs. Consequently,
the in vitro production of these identiﬁed proteomic factors
could provide clues for the production of a deﬁned serum-
free medium for hMSC expansion. Such data derived from
human supplements, along with the advancements in the
statistical and computational strategies, could aid in the
development of a standard, deﬁned medium for clinical
preparations of hMSCs.
When viewed in the context of research, these human
supplements could serve as cheaper alternatives for large-
scale expansion of hMSCs, with better cell proliferation
rates. The eﬃcacy of these medium additives to provide
clinical-grade hMSCs has also been tested for, resulting inStem Cells International 11
satisfactory outcomes, thus, thrusting forward the FBS-free
media bandwagon for stem cell culture. At the moment,
no deﬁnitive serum-free/chemically-deﬁned medium with
all the necessary recombinant growth factors is available for
hMSC ampliﬁcation. Hence, these human growth supple-
ments could serve as transitional elements in the clinical-
scale production of hMSCs, until commercial, safe, oﬀ-the-
shelf alternatives become available.
The establishment of standardized protocols that con-
form to good cell culture practices is of high precedence
in this era of Cell-based therapy and regenerative medicine.
Successful transplantation of the in vitro expanded hMSCs
and assurance of their long-term therapeutic eﬀects, in
vivo, is of paramount importance, to thrust this novel ﬁeld
forward. Once hMSC culture in the clinical setting is well-
established, issues on their large-scale expansion with GMP-
compliant protocols would be the next hot topic for debate.
Therefore, the optimal culture conditions, for the eﬃ-
cient clinical-scale production of hMSCs that are thera-
peutically applicable in transplantation, immunotherapy,
and regenerative medicine, still remain elusive. Despite
these major questions remaining unanswered here, studying
and evaluating the foundations of this issue will deﬁ-
nitely strengthen our knowledge base, helping us make an
informed choice to continue in translational research and
stem cell clinical trials. Continuous research and a growing
interest amongst scientists in this front would deﬁnitely fetch
us a breakthrough in the ongoing pursuit for the optimal
hMSC culture condition.
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